Fresh2FRES
About: Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.
Employees: 75
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 3 [Q2] → 3 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.01% less ownership
Funds ownership: 0.01% [Q2] → 0% (-0.01%) [Q3]
93% less capital invested
Capital invested by funds: $21.7K [Q2] → $1.48K (-$20.2K) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for FRES.